PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Clinical Pharmacology, Hospital Universitario Puerta de Hierro, Madrid, Majadahonda, Spain. cpayares.hpth@gmail.com.\', \'Department of Haematology and Cell Production Unit, Hospital Universitario Puerta de Hierro, Madrid, Majadahonda, Spain.\', \'Department of Intensive Care Medicine, Hospital Universitario Puerta de Hierro, Madrid, Majadahonda, Spain.\', \'Department of Respiratory Medicine, Hospital Universitario Puerta de Hierro, Madrid, Majadahonda, Spain.\', \'Department of Clinical Pharmacology, Hospital Universitario Puerta de Hierro, Madrid, Majadahonda, Spain.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1186/s13063-020-04964-1
?:doi
?:hasPublicationType
?:journal
  • Trials
is ?:pmid of
?:pmid
?:pmid
  • 33407777
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.291
?:rankingScore_hIndex
  • 57
is ?:relation_isRelatedTo_publication of
?:title
  • Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33407777>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33407777>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all